How to alleviate the side effects of resmetirom

Although resmetirom-Rezdiffra has shown obvious advantages in the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis, some patients may experience some uncomfortable reactions during the medication. Common side effects include mild diarrhea, nausea, fatigue, itching, and changes in blood lipids. Most of these side effects are controllable, mild to moderate, and will not seriously affect treatment, but patients still need to pay attention to scientific management and timely relief.

When facing digestive system discomfort, such as diarrhea or mild nausea, patients are advised to follow a light diet, avoid greasy and spicy foods, and appropriately increase foods rich in dietary fiber to maintain intestinal balance. If symptoms persist, the medication time should be adjusted under the guidance of a doctor, or even auxiliary drugs can be considered to relieve it. For fatigue and weakness, maintaining a regular schedule and moderate exercise can help improve your physical condition and avoid overexertion.

Some patients experience skin itching or mild rash, which are usually relieved by keeping the skin clean and using mild emollient. If symptoms worsen, you should communicate with your doctor promptly to avoid stopping the medication on your own. Regarding changes in blood lipid indicators, clinicians will regularly monitor the patient's blood condition and, if necessary, combine it with statins or other lipid-lowering treatments to ensure overall metabolic safety.

More importantly, patients should avoid adjusting dosage or discontinuing medication on their own, and any side effects need to be managed under the guidance of a doctor. Because resmetirox is a long-term treatment drug, patient tolerance will gradually improve over time, and most side effects will not persist. Combined with a healthy diet, exercise habits and regular follow-up, the trouble caused by side effects can be greatly reduced, thereby ensuring the maximum treatment effect.

Reference materials:https://www.drugs.com/monograph/resmetirom.html